Do you experience Endometriosis with moderate to severe pain or Uterine Fibroids with heavy menstrual bleeding?

Endometriosis or Uterine Fibroids

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 4 years and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.

Study information:

  • Condition: Endometriosis Pain OR Uterine Fibroids with Heavy Menstrual Bleeding

  • Location: Mesa, Arizona

  • Duration: Up to 5 years

  • Participation: 10 visits & 14 phone calls

  • Compensation: Up to $4,614

Eligibility:

  • Premenopausal women aged 18 – 50 years

  • Moderate to severe pain associated with Endometriosis

    • OR

  • Heavy menstrual bleeding associated with Uterine Fibroids

  • Other study requirements apply.

Participants may receive:

  • Compensation up to $4,614

  • Regular check-ins with a team of doctors and nurses to monitor your health

  • Diagnostic tests and procedures at no-cost

  • Access to Myfembree® for treatment of heavy menstrual bleeding associated with uterine fibroids or moderate to severe pain associated with endometriosis

Get started today.

You are not committed to participate in a study by completing this form. Participation is voluntary, and you may leave at any time if you change your mind.

Why is this study important?

This study is an open-label study (that means all participants know exactly what medicine they are taking) and no participants will receive placebo pills or sugar pills.

Currently, this medicine is approved by the United States (US) Food and Drug Administration (FDA) for up to 2 years of use for the management of premenopausal women with heavy menstrual bleeding associated with uterine fibroids or moderate to severe pain associated with endometriosis. The purpose of this study is to follow changes in bone mineral density (BMD) over time when Myfembree® (relugolix combination tablet) is used for up to 4 years.